- Home
- MRCC vs IKT Comparison
MRCC vs IKT Comparison
Compare MRCC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- IKT
- Stock Information
- Founded
- MRCC 2011
- IKT 2008
- Country
- MRCC United States
- IKT United States
- Employees
- MRCC N/A
- IKT N/A
- Industry
- MRCC Investment Managers
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- IKT Health Care
- Exchange
- MRCC Nasdaq
- IKT Nasdaq
- Market Cap
- MRCC 176.4M
- IKT 131.6M
- IPO Year
- MRCC 2012
- IKT 2020
- Fundamental
- Price
- MRCC $6.46
- IKT $1.89
- Analyst Decision
- MRCC Hold
- IKT Buy
- Analyst Count
- MRCC 1
- IKT 2
- Target Price
- MRCC $8.00
- IKT $8.00
- AVG Volume (30 Days)
- MRCC 91.8K
- IKT 521.7K
- Earning Date
- MRCC 08-06-2025
- IKT 08-13-2025
- Dividend Yield
- MRCC 15.48%
- IKT N/A
- EPS Growth
- MRCC 3301.50
- IKT N/A
- EPS
- MRCC 0.32
- IKT N/A
- Revenue
- MRCC $56,983,000.00
- IKT N/A
- Revenue This Year
- MRCC N/A
- IKT N/A
- Revenue Next Year
- MRCC N/A
- IKT N/A
- P/E Ratio
- MRCC $19.88
- IKT N/A
- Revenue Growth
- MRCC N/A
- IKT N/A
- 52 Week Low
- MRCC $6.11
- IKT $1.12
- 52 Week High
- MRCC $8.85
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- MRCC 50.70
- IKT 49.15
- Support Level
- MRCC $6.19
- IKT $1.56
- Resistance Level
- MRCC $6.65
- IKT $2.04
- Average True Range (ATR)
- MRCC 0.15
- IKT 0.15
- MACD
- MRCC 0.02
- IKT 0.02
- Stochastic Oscillator
- MRCC 50.88
- IKT 58.95
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.